Correlia Biosystems
Next-gen blood testing to provide 1000x more data to pharma companies
- Status
- Inactive
- Stage
- Growth
- Team size
- 16
- Location
- San Francisco, CA, USA; Berkeley
- Category
- Medical Devices & Diagnostics
- Sector
- Diagnostics
About Correlia Biosystems
Correlia Biosystems is a UC Berkeley spinoff company based in Berkeley, CA. Correlia develops innovative microscale tools that accelerate rapid quantification of biomolecules. Our versatile SimpleScan technology opens up new biological questions from one microliter of sample, with rapid results that allow for dynamic monitoring of protein expression profiles (rather than simple end-point measurement). Applications range from enabling next-gen proteomic data sets to point-of-care diagnostics.
Federal research funding
3 NIH awards totalling $673,898, FY2014 to FY2016.
- Rapid assay platform for POC Hepatitis C core antigen testing
- Electrokinetic Lateral Flow Tests for Rapid Point-of-Care Diagnosis of Sickle Cel
Source: NIH RePORTER.
Securities filings
2 Form D filings on record, 2020 to 2023.
Filed as Correlia Biosystems, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
